Jazz Pharmaceuticals Public Limited Company officer and director Renee D. Gala filed a Form 144 notice on November 3, 2026, disclosing a proposed sale of 1,000 shares of common stock on NASDAQ.

Key Highlights

  • Proposed sale: Renee D. Gala intends to sell 1,000 shares of Jazz Pharmaceuticals common stock with an aggregate market value of $225,370.00.
  • Shares acquired: The 1,000 shares were acquired on June 30, 2026 as restricted stock from the issuer, with payment listed as "Not Applicable."
  • Approximate sale date: The proposed sale is dated November 3, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
  • Shares outstanding: According to the filing, 64,189,052 shares of common stock were outstanding at the time of the notice.
  • Prior sales: Gala sold 2,000 shares on October 6, 2026 for gross proceeds of $472,800.00, and 2,000 shares on September 8, 2026 for gross proceeds of $486,060.00.
  • Rule 10b5-1 plan: The notice indicates a trading plan or instruction date of June 4, 2026.

Details of Renee D. Gala's Proposed Share Sale at Jazz Pharmaceuticals

According to the Form 144 filing dated November 3, 2026, Renee D. Gala, who holds the roles of both officer and director at Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ), disclosed a proposed sale of 1,000 shares of the company's common stock. The aggregate market value of the shares to be sold is listed as $225,370.00. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

The filing states that the 1,000 shares subject to the proposed sale were acquired on June 30, 2026 as restricted stock directly from the issuer. The payment nature is listed as "Not Applicable." The notice also discloses that the sale is being conducted under a Rule 10b5-1 plan or instruction adopted on June 4, 2026, as indicated in the "Date of Plan Adoption or Giving of Instruction" field.

The filing further discloses Gala's securities sold during the prior three months. On October 6, 2026, Gala sold 2,000 shares of common stock for gross proceeds of $472,800.00, and on September 8, 2026, sold an additional 2,000 shares for gross proceeds of $486,060.00. Both prior transactions are attributed to Renee D. Gala at the same issuer address in Dublin, Ireland. Jazz Pharmaceuticals is headquartered at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

What Was Disclosed

Renee D. Gala, an officer and director of Jazz Pharmaceuticals, filed a Form 144 on November 3, 2026, proposing to sell 1,000 common shares valued at $225,370.00, with two prior sales of 2,000 shares each disclosed within the preceding three months.